The process of collecting, preserving, and managing biological samples and associated data for use in research and therapeutic applications is referred to as biobanking. Biobanks can gather a variety of samples, such as blood, tissues, and bodily fluids, as well as clinical data, such as medical histories and lifestyle data. These samples and data are often preserved in biobanks, which are specialized facilities.
Biobanks are increasingly being used in biomedical research and personalized treatment. Biobanks provide researchers with access to large, diverse collections of biological samples and data, which can aid in the discovery of biomarkers for disease detection and diagnosis, the development of personalized treatments based on an individual's genetic makeup, and the advancement of precision medicine. Biobanking also poses ethical and legal problems about sample collection, storage, and usage, such as donor privacy and the requirement for informed permission.
The growing desire for personalised treatment is one of the primary drivers of biobanking. With an increased understanding of individual differences in genetics, lifestyle, and environmental variables, personalised medicine is becoming increasingly crucial for illness prevention and treatment. Biobanks are an important source of data and biological samples for the development of personalised medicine, and demand for biobanking services is projected to increase in the future years.
The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease is another driver of the biobanking business. These diseases place a considerable burden on healthcare systems globally, and their prevalence is anticipated to rise in the coming years as populations age and lifestyles change. Researchers can use biobanks to examine the underlying causes of various disorders, uncover biomarkers for early detection and diagnosis, and develop new treatments.
The expense of collecting, storing, and managing biological samples and data is one possible market barrier for biobanking. Biobanks necessitate large expenditures in infrastructure, equipment, and employees, which might be prohibitively expensive for smaller organizations or research institutes with limited resources. Furthermore, ethical and legal problems about privacy, ownership, and consent may complicate the process of obtaining and using biological samples for research purposes.
The high cost of adopting and maintaining these systems is a major limitation in the Biobanking business. The initial investment in technology and software can be substantial, particularly for smaller healthcare facilities. Furthermore, the complexity of these systems can result in increased training costs and potential user adoption concerns. Concerns about regulatory and data privacy can also be a problem, especially with the rising usage of cloud-based solutions and the need to comply with various data protection standards.
The COVID-19 pandemic has had an impact on the biobanking sector, both positively and negatively. On the one hand, the pandemic has boosted the focus on vaccine and treatment research and development, raising demand for biobanking services and samples. On the other side, supply chain interruptions, restrictions on research efforts, and budget cuts have all had a detrimental impact on the market. In reaction to the epidemic, there has also been a shift towards virtual biobanking systems, as well as a greater emphasis on data management and sharing.
ATTRIBUTE | DETAILS |
Study period | 2020-2030 |
Base year | 2022 |
Estimated year | 2023 |
Forecasted year | 2023-2030 |
Historical period | 2019-2021 |
Unit | Value (USD Billion) |
Segmentation | By Product, By Sample Type, By Application, By Region |
By Product |
|
By Sample Type |
|
By Application |
|
By Region |
|
The biobanking is expected to grow at 7.9% CAGR from 2023 to 2030. It is expected to reach above USD 44.6 billion by 2029 from USD 22.5 billion in 2020.
North America held more than 47% of the biobanking revenue share in 2022 and will witness expansion in the forecast period.
The growing desire for personalised treatment is one of the primary drivers of biobanking. With an increased understanding of individual differences in genetics, lifestyle, and environmental variables, personalised medicine is becoming increasingly crucial for illness prevention and treatment. Biobanks are an important source of data and biological samples for the development of personalised medicine, and demand for biobanking services is projected to increase in the future years.
The Biobanking key Thermo Fisher Scientific, Qiagen, Hamilton Company, Brooks Life Sciences, Tecan Group, VWR International, Promega Corporation, Chart Industries, Bio Life Solutions, Panasonic Healthcare Holdings, Micronics.
Based on product, the biobanking market can be segmented based on equipment, consumables, services, and software. The equipment segment includes freezers, storage systems, and sample management systems. The consumables segment includes storage tubes, sample containers, and other consumables. The services segment includes biorepository, sample processing, and storage services. The software segment includes data management and inventory management software.
The North America region dominated the biobanking by accounting for over 47% of the market share. The biobanking market in North America is expected to grow significantly in the coming years due to increasing investment in research and development activities, advancements in personalized medicine, and rising demand for high-quality biological samples. The United States dominates the market due to its well-established healthcare infrastructure, favorable regulatory policies, and high healthcare spending. Key players in the North American biobanking market include Thermo Fisher Scientific, Qiagen, Incision, and Hamilton Company, among others.
The North America region dominated the biobanking by accounting for over 47% of the market share. The biobanking market in North America is expected to grow significantly in the coming years due to increasing investment in research and development activities, advancements in personalized medicine, and rising demand for high-quality biological samples. The United States dominates the market due to its well-established healthcare infrastructure, favorable regulatory policies, and high healthcare spending. Key players in the North American biobanking market include Thermo Fisher Scientific, Qiagen, Incision, and Hamilton Company, among others.
[caption id="attachment_30015" align="aligncenter" width="1920"]The biobanking market in Europe is projected to grow at a compound annual growth rate of 7.4% from 2023 to 2030. This growth is driven by the increasing demand for personalized medicine, advancements in biobanking technology, and the rising prevalence of chronic diseases. The UK, Germany, and France are the leading countries in the European biobanking market.
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.